S-1929-119
Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (text: CR S3207-3208)
Sponsored by Charles Schumer (D-NY)
What it does
The SEPSIS Act would amend the Public Health Service Act to require the CDC to maintain a dedicated sepsis team focused on hospital education, pediatric data collection, quality measure development, and data sharing across federal health agencies. It would also authorize the Secretary of Health and Human Services to create a voluntary "Honor Roll" recognition program for hospitals that demonstrate effective sepsis prevention and treatment. The bill would authorize $20 million per year for fiscal years 2026 through 2030, totaling $100 million, and require annual congressional briefings and a report on outcome measures within one year of enactment.
Who benefits
Patients hospitalized with or at risk of sepsis — particularly the estimated 1.7 million Americans diagnosed annually. Pediatric patients, who receive specific focus under the bill's data collection provisions. Hospitals that adopt best practices and gain recognition through the Honor Roll program. Infectious disease and infection prevention healthcare workers, whose workforce the bill's findings identify as needing support. Researchers studying sepsis, who would benefit from improved federal data infrastructure. Medicare and Medicaid patients, as CMS would receive shared data to inform quality measures. Communities with high rates of hospital-acquired infections.
Who is hurt
Hospitals that currently do not meet sepsis best-practice benchmarks may face reputational pressure if Honor Roll participation data becomes publicly visible. Taxpayers would bear the cost of the $100 million authorization. Federal agencies — particularly CDC and AHRQ — would absorb new reporting and coordination mandates, potentially diverting staff resources from other programs. Competing public health priorities may receive relatively less attention or funding if appropriations are constrained.
Supporters argue
Supporters argue that sepsis kills 350,000 Americans annually — more than most cancers — and that 80 percent of cases begin outside hospitals, making coordinated federal education and data infrastructure essential. They point to New York State's "Rory's Regulations" as concrete evidence that standardized sepsis protocols reduce preventable deaths, and contend that a $20 million annual federal investment to scale those lessons nationally is modest relative to sepsis being one of the costliest hospital conditions in the country, with one in five patients readmitted within 30 days.
Opponents argue
Opponents argue that the bill creates new federal bureaucratic layers — a permanent CDC sepsis team, annual congressional briefings, and a recognition program — without mandating measurable outcomes or hospital compliance, raising questions about whether $100 million in spending would produce demonstrable reductions in sepsis mortality. They contend that sepsis protocol adoption is already occurring at the state and hospital level, and that voluntary federal education campaigns and honor rolls duplicate existing efforts by organizations like the Society of Critical Care Medicine without clear evidence of added effectiveness.
Constitutional context
Congress has broad authority to fund public health programs under the Taxing and Spending Clause (Art. I, §8, cl. 1) and to regulate healthcare-related interstate commerce under the Commerce Clause (Art. I, §8, cl. 3). Because the bill's hospital recognition program is explicitly voluntary and imposes no mandates on states or private entities, it does not raise the Spending Clause coercion concerns identified in NFIB v. Sebelius (2012). No clear constitutional tension exists here.
Checks and balances
The executive branch (CDC and HHS) gains new programmatic authority and funding; Congress retains oversight through mandatory annual briefings, a required outcome measures report, and the appropriations process, which must authorize funds each fiscal year.
Historical precedent
The Stroke Treatment and Ongoing Prevention Act (STOP Stroke Act) and similar federal public health awareness and data programs have used comparable CDC-centered structures to address specific disease burdens, though no single prior law is a direct analogue for a federal sepsis-specific program of this scope.